logo
menu
01About us
Spin offCollaborationCILoacation
02Platforms
Ocular ImplantsMicroarray Patches
03Pipelines
SMO SeriesSMM SeriesSMZ Series
04Facilities
SMO LineSMM Line1st Site2nd Site
05Business
Business ModelCDMO Business
06Contact us
call@hanlim.com
Home    >    Pipelines    >    SMM SeriesSMM Series

SMM

SMM1
SMM2
SMM3
SMM1 image 1
SMM1 image 2

SMM1 Information

Indication
Osteoporosis
Active Ingredient
Teriparatide
Administration Site
Transdemal Administration
Competing Products
Forteo/Lilly
Milestones
milestones
* The release schedule of SMM1 and SMM2 and SMM3 are subject to change depending on the patent situation of each country
footer-logo
CEO : Jinha Park
Company : SANGMYUNG innovation Co., Ltd.
T : +82 2 3489 6100
Head Office : 2-27, Yeongmun-ro, Cheoin-gu, Yongin-si, Gyeonggi-do, Republic of Korea
Branch Office : 42, Seocho-daero 52-gil, Seocho-gu, Seoul, Republic of Korea
Privacy PolicyCopyright © SANGMYUNG innovation